Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ola Landgren

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Best Practice & Research. Clinical Haematology|March 7, 2020
Multiple myeloma: Current advances and future directionsC Ola Landgren
Best Practice & Research. Clinical Haematology|March 7, 2020
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disordersGary A Ulaner, C Ola Landgren
Best Practice & Research. Clinical Haematology|March 7, 2020
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the futureBenjamin Diamond, Kylee Maclachlan, David J Chung, et al.
The Journal of Applied Laboratory Medicine|October 23, 2019
Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab AssayKatie L Thoren, Matthew J Pianko, Youssef Maakaroun, et al.
Best Practice & Research. Clinical Haematology|March 7, 2020
Second malignancies in multiple myeloma; emerging patterns and future directionsKylee Maclachlan, Benjamin Diamond, Francesco Maura, et al.
Leukemia & Lymphoma|November 7, 2017
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Arnab Ghosh, Sham Mailankody, Sergio A Giralt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 9, 2018
Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample DatabaseYuzhou Liu, Hedong Han, Gunjan Shah, et al.
Blood Reviews|August 11, 2020
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarityBenjamin T Diamond, Even Rustad, Kylee Maclachlan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL AmyloidosisHeather Landau, Oscar Lahoud, Sean Devlin, et al.
Haematologica|September 3, 2021
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controlsUrvi A Shah, Sæmundur Rögnvaldsson, Andriy Derkach, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Best Practice & Research. Clinical Haematology|March 7, 2020
Multiple myeloma: Current advances and future directionsC Ola Landgren
Best Practice & Research. Clinical Haematology|March 7, 2020
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disordersGary A Ulaner, C Ola Landgren
Best Practice & Research. Clinical Haematology|March 7, 2020
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the futureBenjamin Diamond, Kylee Maclachlan, David J Chung, et al.
The Journal of Applied Laboratory Medicine|October 23, 2019
Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab AssayKatie L Thoren, Matthew J Pianko, Youssef Maakaroun, et al.
Best Practice & Research. Clinical Haematology|March 7, 2020
Second malignancies in multiple myeloma; emerging patterns and future directionsKylee Maclachlan, Benjamin Diamond, Francesco Maura, et al.
Leukemia & Lymphoma|November 7, 2017
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Arnab Ghosh, Sham Mailankody, Sergio A Giralt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 9, 2018
Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample DatabaseYuzhou Liu, Hedong Han, Gunjan Shah, et al.
Blood Reviews|August 11, 2020
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarityBenjamin T Diamond, Even Rustad, Kylee Maclachlan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL AmyloidosisHeather Landau, Oscar Lahoud, Sean Devlin, et al.
Haematologica|September 3, 2021
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controlsUrvi A Shah, Sæmundur Rögnvaldsson, Andriy Derkach, et al.
Pageof 2